Lilly's tirzepatide chronic kidney disease Phase 2 closes out

Eli Lilly's Phase 2 study of tirzepatide in people with overweight or obesity and chronic kidney disease, with or without type 2 diabetes, changed status from "active, not recruiting" to "completed" on September 11, 2026, according to a registry change tracked on ClinicalTrials.gov ^[2][1].

The trial, listed under identifier NCT05536804, also had its primary completion date moved earlier, from a listed month of 2026-09 to a specific date of July 6, 2026, a shift of about two months ^[1]. Enrollment for the study was also revised downward, from a planned 140 participants to 134 who were actually included ^[1][2]. Tirzepatide is the active ingredient in Lilly's Mounjaro and Zepbound.

The study is designed to test tirzepatide, known by the compound code LY3298176, in adults who have overweight or obesity along with chronic kidney disease, including participants both with and without type 2 diabetes ^[2]. Because the trial now shows as completed rather than active, the next public step would typically be the posting of results data to the registry, though no results have been reported in the tracked record as of this change ^[1].

This registry update was one of 147 changes recorded by a service that monitors ClinicalTrials.gov listings for GLP-1 drugs, comparing snapshots taken six times a day since it began tracking on August 21, 2026 ^[1]. The tracker exists because ClinicalTrials.gov and the FDA's shortage database each overwrite old values when a record changes, so a shifted completion date or a revised enrollment number is not visible after the fact unless someone recorded the prior version ^[1]. In this case, the old and new values for the tirzepatide kidney trial were both captured: enrollment fell from 140 to 134, and the completion date moved from a vague 2026-09 to the specific date of July 6, 2026 ^[1].

Why it matters for patients

For people with obesity who also have chronic kidney disease, this trial closing out is a step toward finding out whether tirzepatide affects kidney function in that population, separate from any effect on diabetes. The study includes participants both with and without type 2 diabetes, which is relevant because it is testing whether any kidney-related effect shows up regardless of diabetes status ^[2]. A completed status means the study has finished collecting the data it was designed to collect, but it does not mean results are public yet, and no efficacy or safety findings from this specific trial appear in the tracked record ^[1][2].

Patients currently on tirzepatide products such as Mounjaro or Zepbound should not read a completed trial status as new information about approved uses. This is a Phase 2 study, an earlier stage of testing that is used to gather data before a company decides whether to run larger Phase 3 trials that could eventually support a new FDA-approved use ^[2]. Kidney disease has not yet been added as an approved indication for tirzepatide, based on the information available in this record ^[1][2].

What happens next

The registry record does not specify when results from this trial will be posted, only that the primary completion date moved earlier, to July 6, 2026 ^[1]. Because the study is now marked completed rather than active, watchers of the registry expect a results submission or a related announcement to follow, though the tracked source material does not give a firm date for when that will happen ^[1]. Broader activity in the tirzepatide and semaglutide pipeline continues, including other Phase 2 and Phase 3 studies tracked in the same monitoring period, though those studies address different conditions and are not directly tied to this kidney trial ^[1].